Commerce Impacts Access to ‘Artificial Pancreas’ for US Patients

In addition to the commercial space, 16 State Medicaid plans “have published CGM policy that does not limit access to the MiniMed 670G system,” he added.

JDRF has just launched a new phase of its “Coverage2Control” campaign urging insurers not to restrict patient choice regarding diabetes technologies.

“Through these and other efforts, it’s our goal to ensure that people with type 1 diabetes continue to have treatment options, as we work toward our ultimate vision of a world without type 1 diabetes,” the organization notes in a statement.

For more diabetes and endocrinology news, follow us on Twitter and on Facebook.